ATE174063T1 - Mit psoralen konjugierte methylphosphonat- oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie - Google Patents

Mit psoralen konjugierte methylphosphonat- oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie

Info

Publication number
ATE174063T1
ATE174063T1 AT91915657T AT91915657T ATE174063T1 AT E174063 T1 ATE174063 T1 AT E174063T1 AT 91915657 T AT91915657 T AT 91915657T AT 91915657 T AT91915657 T AT 91915657T AT E174063 T1 ATE174063 T1 AT E174063T1
Authority
AT
Austria
Prior art keywords
psoralen
myological
leukemia
chronic
therapeutic agents
Prior art date
Application number
AT91915657T
Other languages
English (en)
Inventor
Moretza M Vaghefi
Mark A Reynolds
Lyle J Arnold Jr
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Application granted granted Critical
Publication of ATE174063T1 publication Critical patent/ATE174063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT91915657T 1990-08-09 1991-08-09 Mit psoralen konjugierte methylphosphonat- oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie ATE174063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56529990A 1990-08-09 1990-08-09

Publications (1)

Publication Number Publication Date
ATE174063T1 true ATE174063T1 (de) 1998-12-15

Family

ID=24258000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915657T ATE174063T1 (de) 1990-08-09 1991-08-09 Mit psoralen konjugierte methylphosphonat- oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie

Country Status (11)

Country Link
EP (1) EP0542887B1 (de)
JP (1) JPH06500322A (de)
KR (1) KR930701627A (de)
AT (1) ATE174063T1 (de)
AU (2) AU8400391A (de)
CA (1) CA2089088A1 (de)
DE (1) DE69130569T2 (de)
IE (1) IE912806A1 (de)
IL (1) IL99069A (de)
NZ (1) NZ239252A (de)
WO (1) WO1992002641A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590090A4 (de) * 1991-06-18 1995-04-12 Univ Temple Selektive hemmung leukämischer zellproliferation durch -i(bcr-abl) antisens-oligonukleotide.
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5556993A (en) 1993-06-28 1996-09-17 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US6420570B1 (en) 1993-06-28 2002-07-16 Cerus Corporation Psoralen compounds
US5399719A (en) 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
DE69819360T2 (de) 1997-11-20 2004-08-19 Cerus Corp., Concord Neue psoralene zur inaktivierung von pathogenen
EP4082551A1 (de) 2006-08-08 2022-11-02 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur und verwendung von 5'-phosphat-oligonukleotiden
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
EP4371992A1 (de) * 2022-11-17 2024-05-22 YongNong BioSciences Co., Ltd Verfahren zur herstellung von glufosinat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88550A (pt) * 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas
PT88665B (pt) * 1987-10-05 1992-12-31 Ml Tecnology Ventures Lp Metodo para a marcacao com ester de acridinio e purificacao de sondas nucleotidicas
US4999290A (en) * 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
NZ239250A (en) * 1990-08-09 1993-12-23 Genta Inc Chirally pure non-nucleotide reagents for use in preparing

Also Published As

Publication number Publication date
KR930701627A (ko) 1993-06-12
AU5618096A (en) 1996-10-10
AU693690B2 (en) 1998-07-02
CA2089088A1 (en) 1992-02-10
EP0542887B1 (de) 1998-12-02
WO1992002641A1 (en) 1992-02-20
AU8400391A (en) 1992-03-02
IL99069A (en) 1998-08-16
DE69130569D1 (de) 1999-01-14
JPH06500322A (ja) 1994-01-13
EP0542887A4 (en) 1993-09-08
IE912806A1 (en) 1992-02-12
DE69130569T2 (de) 1999-05-27
NZ239252A (en) 1997-07-27
IL99069A0 (en) 1992-07-15
EP0542887A1 (de) 1993-05-26

Similar Documents

Publication Publication Date Title
ATE174063T1 (de) Mit psoralen konjugierte methylphosphonat- oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
RU95110871A (ru) Способы определения нуклеотидной последовательности
FI905327A0 (fi) Foerfarande foer blekning av massa utan klor.
ATE332368T1 (de) Selektion von proteinen mittels rns-protein fusionen
DE69431485D1 (de) Doppelsträngige peptidenukleinsäuren
PT653439E (pt) Oligonucleotidos e sua aplicacao
DE59108644D1 (de) Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
NO994413D0 (no) Kationiske lipidblandinger mÕlsökende angiogene endotelceller
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
FI920760A0 (fi) In vitro packningsystem foer kloning av dna-fragment med 95 kb.
FI913391A0 (fi) Foerfarande foer detektering av smaocellcarcinom och anvaendning av acylpeptidhydrolas och denna kodande sekvenser.
FR2770521B1 (fr) Procede de deshydrogenation d'hydrocarbures aliphatiques satures en hydrocarbures olefiniques
DE69106562D1 (de) Oberfläche mit verringerter Proteinwechselwirkung.
DE69831229D1 (de) Schnelle bestimmung des verhältnisses von biologischen molekülen
DE58907786D1 (de) Optische Messanordnung zum Nachweis von Kavitationsblasen in Flüssigkeiten.
DK0986568T3 (da) Kationiske midler til transfektion af nukleinsyrer
BR8907807A (pt) Copolimeros de alfa-olefina funcionalizados com distribuicao estreita de peso molecular
DK37990A (da) Dna-probe
BR8702121A (pt) Alvejamento do caulim com aluminio
FR2652495B1 (fr) Sonde ano-rectale.
ES2137610T3 (es) Somier.
FR2676222B1 (fr) Procede de deshydrogenation d'hydrocarbures aliphatiques en hydrocarbures olefiniques.
ES1041047U (es) Soporte publicitario.
BR8705550A (pt) Alvejamento de caulim com aluminio
IT218397Z2 (it) Piano di lavoro regolabile.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties